Effect of Everolimus on Pharmacokinetics of Octreotide LAR in Patients with Advanced Neuroendocrine Tumors: A RADIANT-2 Analysis

#499

Introduction: In RADIANT-2 (NCT00412061), Everolimus (E) plus Octreotide LAR (O) exhibited a clinically meaningful 5.1-month improvement in progression-free survival (PFS) v. placebo plus octreotide LAR (P+O) in patients (pts) with advanced neuroendocrine tumors (NET) and a history of carcinoid syndrome.

Aim(s): To characterize the effects of coadministration of E on the pharmacokinetics of O.

Materials and methods: Four-hundred and twenty-nine pts with advanced NET received E+O (n=216) or P+O (n=213). The effect of E on O trough concentrations (Cmin) was assessed by a linear mixed-effect model.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pavel M, Grosch K, Cheung W, Hasskarl J, Becerra C,

Keywords: mTOR, somatostatin analog, Everolimus, Octreotide ,